The side effect profile of apomorphine SL (2 -6 mg) has been determined in clinical studies of over 5000 patients using over 120 000 doses. Apomorphine, 2 and 3 mg, has been shown to have an excellent safety profile. The most commonly occurring side effects ( < 7%), nausea, headache and dizziness, tend to be mild and not compliance limiting. Neither the incidence nor the nature of the side effects is significantly affected by common co-morbidites or by the use of many concurrent medications. Over this dose range there is little evidence of vasoactivity; there is little change in haemodynamic baseline and there is no synergistic effect with nitrates. Although syncope can occur at higher doses, it is rarely observed at approved doses ( < 0.2%).
Introduction
Apomorphine SL has completed development as an effective treatment for erectile dysfunction (ED) of varied aetiologies, 1,2 with a rapid onset of action. The rationale for the development of the sub-lingual formulation, described elsewhere, 3 was to circumvent some of the shortcomings of existing therapy. In particular the route of administration and the specific formulation were developed to ensure control and rapidity of onset and provide a greater separation of the optimal dose range for efficacy and any compliance limiting side effects associated with less sophisticated forms of administration.
Methods
The data presented here are a cross-study analysis of the clinical profile of the approved 2 and 3 mg doses of apomorphine SL with reference to higher doses when appropriate. One of the most important studies analysed is a crossover study, 1 comparing 3 mg apomorphine SL with placebo with a dose higher than recommended (4 mg). 1 This safety review represents an analysis of a database of over 5000 patients and over 120 000 individual drug doses of apomorphine SL (2 -6 mg). Additional information on the overall benefit risk ratio of the recommended doses was gleaned from long term studies and a 2, 3 and 4 mg dose optimisation study. 4 
Results
To help put the tolerability results into context it is important to note in the studies summarised that apomorphine SL produced a rapid response with 71% of erections occurring within 20 min. In addition efficacy was consistent (74% to 220% above baseline) irrespective of the severity of the ED, the underlying aetiology and=or the presence of significant co-morbidities (coronary artery disease, hypertension etc). The response was found to be optimal at 2 and 3 mg with no appreciable additional benefit being achieved at higher doses. The apomorphine SL 2 and 3 mg database represents a more severe ED patient population than that described in the Massachusetts Male Ageing Study (MMAS), 5 however, the incidence of co-morbidities is similar (Table 1) .
In the dose optimisation study, as expected, there was a dose-related increase in side effects (Table 2) . At the recommended doses of 2 and 3 mg, the discontinuation rate due to drug related adverse events was 2.3%. 4 The overall incidence of side effects of 2 and 3 mg combined is shown in Table 3 . At the approved doses of 2 and 3 mg, the predominant, although seldom compliance limiting, side effects were nausea (6.8%), headache (6.7%) and dizziness (4.4%).
In general the nausea was mild, transient and selflimiting. Although anti-emetics were offered prophylactically, they were seldom used (0.7%) and when used they did not interfere with the erectile responses. Equally, the relatively few patients experiencing nausea did not experience a diminution of the erectile response to apomorphine SL.
Importantly, tolerance to the nausea has been demonstrated in patients taking at least 8 doses of apomorphine SL 3 mg (Figure 1 ). 4 However, there is no evidence of tolerance developing to efficacy in long term studies of apomorphine SL 2 mg (Figure 2) . 4 As anticipated, the majority of patients in the clinical programme were using concurrent medications ( Table 4) . As in the case of the erectile response, 1,2 there was no evidence that the use of any particular concurrent therapy altered the side effect profile of apomorphine SL. In subgroup analysis, no clinically meaningful differences were observed in adverse event rates in patients with: Adverse events reported by > 1.5% of patients at any given dose. Tolerance to nausea with time Safety and tolerability of apomorphine S Bukofzer and N Livesey hypertension; coronary artery disease; benign prostatic hyperplasia; or diabetes. In extensive cardiovascular evaluations apomorphine SL even at doses as high as 5 mg had minimal effect on either diastolic or systolic blood pressure ( Figure 3 ). 4 Overall there was a mean maximum reduction of about 2 -3 mmHg relative to placebo. A similar 'additive' reduction was seen at this higher than recommended dose of apomorphine SL in patients receiving concurrent long acting nitrates ( Figure 4 ). 4 It is pertinent to note that the clinical profile of apomorphine in the presence of nitrates is qualitatively and quantitatively distinct from that of sildenafil ( Figure 4 ). 6 The latter shows the classical precipitous drops in blood pressure that are characteristic of a 'synergistic' or supra-additive effect with baseline nitrates.
The incidence of syncope has been shown to be dose-related and in the approved dose range the overall incidence is less than 0.2%. In most cases syncope was preceeded by prodromal symptoms including nausea, dizziness and sweating.
In summary, over 5000 patients have been studied with over 200 being followed for more than 1 y. After 120 000 doses administered in clinical trials, no deaths related to the study drug have been observed. Furthermore there were no myocardial infarctions or cerebrovascular accidents. No priapism has been observed and no inappropriate erections reported.
Discussion
The consistency and durability of the erectile response to apomorphine SL is now well documented. 1 -3 The drug has been found to work effectively in patients with a wide range of ED aetiologies, severities and co-morbidites. However, a key issue in the development of a drug is the selection of the most appropriate dose(s). In the efficacy studies, it has been found that maximal benefit can be achieved at 2 or 3 mg, with little additional benefit being observed at higher doses. However, an important part of the drug development process is the quantification of benefit risk and the assessment of the side effect profile of any drug over the anticipated dose range and at higher doses.
It is clear that apomorphine SL is well tolerated with a low discontinuation rate (2.3%) due to adverse events at 2 and 3 mg. With the caveat that patients in clinical trials particularly for this type of disorder are relatively highly motivated, this, compared to historical clinical development programmes, represents a remarkably low discontinuation rate. The corollary is that this contributes to a high 'satisfaction rate' which could in turn reflect the long-term durability and consistency of the erectile response shown in Figure 2 . Figure 3 The effect of apomorphine SL on diastolic and systolic supine and standing blood pressure. Although changes may achieve statistical significance, they are of limited clinical significance.
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In general terms, the major side effects, although occurring in less than 7% of patients, are nausea, headache and dizziness. The nausea tends to be mild and self-limiting. Over the approved dose range of apomorphine SL there is little or no evidence of the emesis that has been observed with apomorphine when delivered by other routes eg subcutaneously, or at higher doses in other formulations. It would therefore appear that the theoretical predictions on the separation of erectile response and side effects particularly (see Figure 5 ) are clinical reality.
It is important to note that neither the efficacy nor tolerability of apomorphine SL are significantly affected by the co-morbidites commonly associated with ED or indeed by many of the concurrent medications that might be taken by ED patients. However, it is clear that there is no 'average' ED patient and no trial can be entirely predictive of all eventualities. It is pertinent to note that the overall incidence of side effects is lower than those for other agents widely used in the treatment of other urological conditions eg alpha-blockers in benign prostatic hyperplasia. 
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Conceptual dopamine agonist receptor Figure 5 This represents a theoretical model for the interaction of apomorphine with various dopamine dependent systems. This is based on the known pharmacokinetic characteristics of apomorphine SL, its distribution into various compartments of the biophase and the pharmacology of its interaction with dopamine receptor subtypes.
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The arrival of sildenafil created an increasing awareness and debate on the use of drugs for ED and cardiovascular risks that is outside the scope of this discussion. However, it is obvious that there is no general association between renewed sexual activity and cardiovascular morbidity or mortality. 7 The clinical database on apomorphine is entirely consistent with this. In all studies there were no drug-related deaths, myocardial infarctions or cerebrovascular accidents.
The effects of apomorphine on the haemodynamic baseline are relatively modest. Even at the relatively high dose of 5 mg, mean diastolic blood pressure was only changed by 2 -3 mm=Hg, relative to placebo. Although further studies are necessary, it is unlikely that the addition of apomorphine SL will alter the cardiovascular control in controlled hypertensive patients. This would be consistent with the benign side effect profile in the 30% of ED patients who were on concomitant antihypertensive therapy.
The slight effect of apomorphine SL on the haemodynamic baseline can also be observed in the study in patients on long-term nitrates ( Figure  4 ). As might be anticipated, from the volunteer studies there was a slight reduction in both diastolic and systolic blood pressure. However, it is important to note that the profile of the 'interaction' was qualitatively and quantitatively distinct from that of the characteristic well-documented profile of sildenafil. 6 The latter, under similar experimental conditions will produce precipitous drops in blood pressure.
Syncope was observed infrequently in clinical studies. When observed, this phenomenon occurred in a dose related manner and, at the recommended doses, the incidence was < 0.2%. Furthermore, syncope was generally preceded by a prodrome of symptoms, including nausea, dizziness and sweating.
Overall it can be concluded that apomorphine SL has an excellent benefit risk ratio at the approved doses of 2 and 3 mg. The most commonly observed side effects, nausea, headache and dizziness tend to be mild, transient and self limiting and seldom affect compliance. At 2 and 3 mg, apomorphine SL only has modest cardiovascular effects. Although there may be a slight predictable additive effect with nitrates, the magnitude and the profile of the response is significantly different from sildenafil. Syncope can occur at higher doses but does so only rarely within the approved dose range. There is no evidence that the side effect profile is significantly affected by associated co-morbidities or by many of the drugs likely to be taken concurrently by the ED patient.
